New study to track Real-World results of HIFU for prostate cancer

NCT ID NCT07203482

Recruiting now Knowledge-focused Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study will follow 300 men with early-stage prostate cancer who choose to be treated with high-intensity focused ultrasound (HIFU). Researchers will collect data on side effects, cancer control, and urinary and sexual function over time. The goal is to better understand how well HIFU works and help guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: High-intensity focused ultrasound (HIFU) ablation
What this could lead to: If successful, this study could provide reliable data to guide treatment decisions and improve care for men with localized prostate cancer.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICALLY LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

NYU Langone Health - Cobble Hill
RECRUITING

Brooklyn, New York, 11201, United States
NYU Langone Health - Tisch Hospital
RECRUITING

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.